In a world where doing a little bit of everything has become popular among drug companies, Mylan (MYL) has stuck to its guns. Unlike Teva (TEVA) and Sandoz (part of Novartis (NVS)), Mylan really is just about generic drugs and the opportunity to leverage one of the largest global franchises in that segment of the drug market. At the bottom line, Mylan is an interesting investment prospect, but really needs to deliver more to be a top choice.
Ending The Year In Line
Mylan did not offer a lot of surprises to close this fiscal year. Revenue rose about 7%, with generics up about 5% overall and the small (less than 10%) specialty business up almost 38%. The generics business was definitely a haves-and-have-not situation this quarter, as the North American business grew almost 13% on good volumes and strong pricing, while the European business saw revenue drop 12% on weak pricing.
Please click the link for the full piece:
Mylan Looks To Reap A Harvest Of Patent Expirations
Showing posts with label Momenta Pharmaceuticals. Show all posts
Showing posts with label Momenta Pharmaceuticals. Show all posts
Wednesday, February 22, 2012
Thursday, August 4, 2011
Investopedia: Teva And Mylan Show Some Value Remains in Generics
Generic drug company stocks have been all over the map this year, with companies like Teva (Nasdaq:TEVA) struggling, companies like Watson (NYSE:WPI), and the likes of Mylan (NYSE:MYL) and Impax (Nasdaq:IPXL) falling somewhere in between. While the sector is still broadly benefiting from popular branded drugs going off patent, pressures from large buyers like AmerisourceBergen (NYSE:ABC) and Cardinal Health (NYSE:CAH) and declining patient-doctor visits are making for a more challenging operating environment.
Mylan - Good Here, Not So Good Over There
Mylan reported 15% revenue growth (10% in constant currency), with North American sales rising over 27%. Asia-Pacific sales also grew by 17%, but Europe was flat as reported and down double-digits on a constant currency basis due in part to government-mandated price cuts in many European markets.
Continue to the full story via this link:
http://stocks.investopedia.
Mylan - Good Here, Not So Good Over There
Mylan reported 15% revenue growth (10% in constant currency), with North American sales rising over 27%. Asia-Pacific sales also grew by 17%, but Europe was flat as reported and down double-digits on a constant currency basis due in part to government-mandated price cuts in many European markets.
Continue to the full story via this link:
http://stocks.investopedia.
Tuesday, August 10, 2010
Biosimilars - The Next Generics Honeypot
Quick correction - I mistakenly indicated that Momenta/Novartis has a window of exclusivity with its generic Lovenox. The first-to-file rule is not in effect here and Teva does not have any sort of statutory waiting period to deal with. I apologize for the error.
Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India's Dr. Reddy's Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals (Nasdaq:TEVA) have certainly produced ample rewards for long-term investors.
Now, though, there is a whole new window of opportunity opening for the generics companies - the opportunity to sell what amount to generic versions of biopharmaceuticals. Though the path will be difficult and expensive, this market represents a major opportunity for the generics industry and potentially a major threat for many large pharmaceutical companies.
To read the complete article, please go to:
http://stocks.investopedia.
Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India's Dr. Reddy's Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals (Nasdaq:TEVA) have certainly produced ample rewards for long-term investors.
Now, though, there is a whole new window of opportunity opening for the generics companies - the opportunity to sell what amount to generic versions of biopharmaceuticals. Though the path will be difficult and expensive, this market represents a major opportunity for the generics industry and potentially a major threat for many large pharmaceutical companies.
To read the complete article, please go to:
http://stocks.investopedia.
Thursday, July 29, 2010
Profit From Teva's Travails
Without question, I have made more money by investing in stocks beaten down by over-heated worries than any other way. This comes to mind when I look at Teva (Nasdaq:TEVA), the world's largest generic pharmaceuticals company. While Teva management seems to be addressing these concerns as directly as they can, the stock's valuation suggests that investors might still have room to profit from Wall Street's lingering doubts.
The Quarter That Was
Teva's June quarter certainly did not provide any particular causes for concern. Revenue rose 12% to $3.8 billion, as the company saw high-teens growth in the North American business. Teva's largest single product, the MS drug Copaxone, saw revenue grow 13% to a bit under $800 million, as strong North American sales offset weaker European results.
The profit side of the ledger was likewise solid and mostly uneventful. Gross margin ticked up a bit, but the company saw good leverage on the sales and marketing lines. Some of this improvement was a result of synergies from acquisitions (including Barr), but some as well came from the end of payments to Sanofi-Aventis (NYSE:SNY) relating to Copaxone. The end result, then, was 22% operating income growth and 30% EPS growth.
To read the complete column, please click through to:
http://stocks.investopedia.
The Quarter That Was
Teva's June quarter certainly did not provide any particular causes for concern. Revenue rose 12% to $3.8 billion, as the company saw high-teens growth in the North American business. Teva's largest single product, the MS drug Copaxone, saw revenue grow 13% to a bit under $800 million, as strong North American sales offset weaker European results.
The profit side of the ledger was likewise solid and mostly uneventful. Gross margin ticked up a bit, but the company saw good leverage on the sales and marketing lines. Some of this improvement was a result of synergies from acquisitions (including Barr), but some as well came from the end of payments to Sanofi-Aventis (NYSE:SNY) relating to Copaxone. The end result, then, was 22% operating income growth and 30% EPS growth.
To read the complete column, please click through to:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)